Head-to-head · WeighScore
Gala Health vs Klinic
The verdict
Gala Health takes it — 82.9/100 to 60.8/100.
Gala Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A compounded tirzepatide and semaglutide program for women that reaches all 50 states and keeps a brand-name Ozempic path open — but its $179 and $149 headline rates are yearly-subscription prices, not monthly ones.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Gala Health | Klinic |
|---|---|---|
| WeighScore | 82.9/100 | 60.8/100 |
| Grade | B− | C |
| Scorecard rank | #17 | #313 |
| Semaglutide | Not disclosed | Not disclosed |
| Tirzepatide | $179/mo (yearly subscription) | Not disclosed |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #17 · B−
Strengths
- Low compounded entry if you prepay the year — $179/mo tirzepatide and $149/mo microdose on the yearly subscription, $199/mo on a 3-month plan
- Prices are published openly rather than quiz-gated, with all doses included at the one rate
- All 50 states and LegitScript-verified, with a brand-name Ozempic path kept open ($1,299)
- HRT and menopause care available alongside GLP-1
Where it loses points
- No month-to-month price is published anywhere — the $179 tirzepatide and $149 microdose rates are both yearly subscriptions, and the shortest term Gala names is a 3-month plan at $199/mo
- Compounded formulations are not FDA-approved
- Brand-name Ozempic is priced steeply at $1,299
- No oral or sublingual route offered yet — injection only
- Newer operator (Gala GLP-1 by AI Coaching Inc) with no named clinicians and no named dispensing pharmacy
Graded #313 · C
Strengths
- LegitScript certified, licensed in all 50 states, DEA registered, HIPAA/SOC 2 Type II compliant
- Broad insurance acceptance including Medicare, Medicaid, BCBS, Aetna, Cigna, UHC, and Humana
- Klinic handles all prior authorization—patient never manages PA paperwork
- Brand-name FDA-approved GLP-1s (Wegovy, Zepbound) at full clinical doses with home delivery
- Named clinical leadership (CMO Dr. Saba Haq, Chief Physician Dr. Vivek Chander) and disclosed founder
Where it loses points
- Brand-name meds are costly self-pay: Wegovy ~$499/month, Zepbound ~$299/month (med cost alone; consult extra)
- No compounded semaglutide or tirzepatide option for patients seeking lower-cost alternatives
- Medication cost is separate from visit fees ($99 initial, $75 follow-up) — total self-pay cost is higher
- No labs or dedicated nutrition/coaching program included in any plan
- Pharmacy fulfillment via Klinic Pharmacy Hub Services LLC (non-dispensing hub); actual dispensing is third-party
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.